摘要
Abstract
Objective To investigate the in newly diagnosed type 2 diabetic patients, the clinical ef ect observed choice Gan Shulin 30R+ metformin after completing treatment. Methods Selected in our hospital in 2010 01 on Sept. 01~ October 1, 2014 in newly diagnosed type 2 diabetic patients in 206 cases. Complete randomized grouping in patients with type 2 diabetes mel itus by random number table method. C1 group (observation group 103 cases):clinical choice Gan Shulin 30R+ metformin treatment;group C2 (control group 103 cases):clinical choice Gan Shulin 30R treatment. Comparison between two groups of diabetic patients in the FPG and 2hPG index show etc. Results The two groups of patients with type 2 diabetes mel itus after completing treatment, in FPG (fasting blood glucose) index (2H and 2hPG postprandial blood glucose) in two indexes, compared with before treatment, showed decreased significantly ( <0.05); C1 group decreased obviously in the patients of group C2 significantly ( <0.05). In the glucose standard time, group C1 was less than that in C2 group were significantly ( <0.05). In the clinical adverse reactions, no significant dif erence between the groups for the performance ( >0.05). Conclusion For newly diagnosed patients with type 2 diabetes, clinical choice Gan Shulin 30R+metformin treatment, can ef ectively guarantee the safety of treatment of patients, showed significance in shortening the patients blood glucose time etc.关键词
甘舒霖30R/二甲双胍/初诊2型糖尿病/疗效/安全性Key words
Gan Shulin 30R/Metformin/type 2 diabetes mel itus/Ef icacy/Safety
